Working… Menu
Trial record 1 of 1 for:    Pf-114 | Russia
Previous Study | Return to List | Next Study

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02885766
Recruitment Status : Active, not recruiting
First Posted : August 31, 2016
Last Update Posted : February 17, 2020
Data Matrix Solutions
Skolkovo Innovation Center
Information provided by (Responsible Party):
Fusion Pharma LLC